⚠️ This study is no longer recruiting participants. This information is provided for reference purposes only.
THARROS: CORONARY ARTERY DISEASE/ COPD Trial
BREZTRI VS BEVESPI: ENDPOINT IS LESS CARDIAC EVENTS MI and CVA
The THARROS study was designed for COPD patients who also have coronary artery disease or are at high risk for cardiovascular events. This trial compared two different inhaled medications, Breztri and Bevespi, to see which is more effective in reducing the risk of heart attacks and strokes in this patient population.
Eligibility Criteria
- Age: 40-80 years
- COPD diagnosis: Post-bronchodilator FEV1/FVC ratio < 70%
- Smoking history: ≥ 10 pack-years (current or former smokers)
- Blood eosinophil count: ≥ 100 cells/mm3
- CAT score: ≥ 10 (phlegm and cough items ≥ 2 each)
- At least one Cardiovascular (CV) criteria met:
- Established CV disease (min. 50% of participants)
- Combination of 3 out of 5 CV risk factors
- High CV risk score on validated assessment tool
- Significant coronary artery calcification with additional risk factor
- Willing to adjust current COPD therapy as required
Key Exclusion Criterion
Use of maintenance inhaled corticosteroid (ICS) treatment more than 2 months within the past 12 months.
Other exclusion criteria include active asthma, end-stage renal disease, recent heart/lung transplant, unstable cardiac disease, recent pneumonia or COPD exacerbation, and participation in another clinical study recently.
Study Outcomes
This study has concluded enrollment and is in the data analysis phase. For information about current or upcoming clinical trials for COPD and heart disease, please contact our research team.